A Study in Healthy Volunteers to Assess Effect of AZD6765 on Midazolam Blood Levels

Completed · Phase 1

Conditions studied: Healthy

In brief

The main purpose of this study is to evaluate the effect repeated doses of AZD6765 (a drug being developed for the treatment of patients with severe major depressive disorder) has on the PK (pharmacokinetic) profile of Midazolam. (The PK profile is how the drug leaves your body and acts in the body.)

Key facts

Study ID

NCT01069822

Run by

AstraZeneca

People needed

46

Starts

2010-02-01

Expected to finish

2010-05-01

Last updated by the study team

2014-10-13

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• BMI between 19-30

You may not qualify if…

• Significant result for C-SSRS at screening or baseline
• Single arm preference for IV procedures

Where it is running

• Research Site — Overland Park, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.